We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Risperdal Gains FDA Approval for Two Adolescent Mental Conditions
Risperdal Gains FDA Approval for Two Adolescent Mental Conditions
August 24, 2007
The FDA approved two supplemental new drug applications for Johnson & Johnson’s (J&J) atypical antipsychotic Risperdal as a short-term treatment for both schizophrenia in adolescents ages 13 to 17 and manic or mixed episodes of bipolar I disorder in children ages 10 to 17, the agency announced Aug. 22.